



King Saud University
Arabian Journal of Chemistry

www.ksu.edu.sa
www.sciencedirect.com



ORIGINAL ARTICLE

Synthesis of 3,4,5-trihydroxybenzohydrazone and evaluation of their urease inhibition potential

Muhammad Taha ^{a,b,*}, Syed Adnan Ali Shah ^{a,c}, Ajmal Khan ^e, Fiza Arshad ^d,
Nor Hadiani Ismail ^{a,b}, Muhammad Afifi ^{a,c}, Syahrul Imran ^{a,b},
Muhammad Iqbal Choudhary ^d

^a Atta-ur-Rahman Institute for Natural Product Discovery, Universiti Teknologi MARA, Puncak Alam Campus, Malaysia

^b Faculty of Applied Science Universiti Teknologi MARA, 40450 Shah Alam, Selangor D. E., Malaysia

^c Faculty of Pharmacy, Universiti Teknologi MARA, Puncak Alam, 42300 Selangor, Malaysia

^d H.E.J. Research Institute of Chemistry, International Center for Chemical and Biological Sciences, University of Karachi, Karachi 75270, Pakistan

^e Department of Chemistry, COMSATS Institute of Information Technology, Abbottabad-22060, Pakistan

Received 2 March 2015; accepted 27 June 2015

KEYWORDS

3,4,5-Trihydroxybenzohydrazones;
Urease inhibition;
Kinetic study

Abstract In the continuation of our work to synthesize enzyme inhibitors, we synthesized 3,4,5-trihydroxybenzohydrazones (**1–19**) from 3,4,5-trihydroxybenzohydrazide, which were obtained from methyl 3,4,5-trihydroxybenzoate by refluxing with hydrazine hydrate. All the synthesized compounds were characterized by different spectroscopic methods. The synthesized compounds were evaluated for urease inhibition and showed excellent results, close to the standards thiourea. The kinetic studies on the five most active compounds **6**, **10**, **14**, **16** and **18** were carried out to determine their mode of inhibition and dissociation constant K_i . The compounds **6** and **16** were found to be competitive inhibitors with K_i values 19.1 and 10.53 μM , respectively, while the compounds **10**, **14** and **18** were found to be mixed-type of inhibitors with K_i values in the range of 18.4–21.7 μM .

© 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

1. Introduction

Applications of benzohydrazones are reported in medicinal and analytical chemistry (Cimerman et al., 2000; Taha et al., 2014; Tarafder et al., 2002). Benzohydrazones having heterocyclic rings were reported to have antiglycation, anticonvulsant, Phosphodiesterase-1 inhibitors, antiproliferative, antifungal and anti-HIV activities (Kabak et al., 1999; Küçükgülzel et al., 2004; Khan et al., 2014a; Jamil et al., 2015; Pandeya et al., 1999). Several benzohydrazones reported interesting bioactivities, such as antifungal, anticonvulsant, anti-inflammatory,

* Corresponding author at: Atta-ur-Rahman Institute for Natural Product Discovery, Universiti Teknologi MARA, Puncak Alam Campus, Malaysia. Tel.: +60 193098141.

E-mail addresses: taha_hej@yahoo.com, muhamm9000@puncakalam.uitm.edu.my (M. Taha).

Peer review under responsibility of King Saud University.




Production and hosting by Elsevier

<http://dx.doi.org/10.1016/j.arabjc.2015.06.036>

1878-5352 © 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University.

This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Please cite this article in press as: Taha, M. et al., Synthesis of 3,4,5-trihydroxybenzohydrazone and evaluation of their urease inhibition potential. Arabian Journal of Chemistry (2015), <http://dx.doi.org/10.1016/j.arabjc.2015.06.036>



Scheme 1 Synthesis of 3,4,5-Trihydroxybenzohydrazones (**1–19**).

antibacterial, antimalarial, antiplatelets, analgesic, antituberculosis, antioxidant (Loncle et al., 2004; Küçükgülzel et al., 2003; Todeschini et al., 1998; Melnyk et al., 2006; Lima et al., 2000; Cunha et al., 2003; Kaymakçioğlu et al., 2006; Aziz et al., 2014), antileishmanial, insecticidal, immunoconjugates, antimycobacterial, adriamycin proteinase inhibition and activity against protozoan parasite (Sawada et al., 2003; Taha et al., 2013; Küçükgülzel and Rollas, 2002; Greenfield et al., 1990; Caffery et al., 2002). Other benzohydrazone derivatives have reported β -glucuronidase (Jamil et al., 2014) and α -glucosidase inhibition activity (Taha et al., 2015a). On the other






hand, substituted acylhydrazide Schiff bases have shown a broad range of bioactivities, including antiurease (Taha et al., 2015b), and antibacterial activities (Imran et al., 2014). Hydrazone derivatives also have several commercial applications (Ragnarsson, 2001).

Urease (E.C 3.5.1.5) plays an important role in the virulence of some bacterial pathogens as well as determinant in pathogenesis of many diseases in human. It is involved in the production of infectious stones; add to the pathogenesis of urolithiasis, pyelonephritis, and hepatic encephalopathy (Weatherburn, 1967). The urease results in pathologies by

Table 1 *In vitro* urease inhibition **1–19**.

Compound	R	IC ₅₀ ($\mu\text{M} \pm \text{SEM}^{\text{a}}$)	Compound	R	IC ₅₀ ($\mu\text{M} \pm \text{SEM}^{\text{a}}$)
1		37.30 \pm 1.4	11		40.20 \pm 1.6
2		57.40 \pm 2.2	12		53.90 \pm 1.8
3		47.40 \pm 1.8	13		55.40 \pm 1.9
4		38.40 \pm 1.4	14		30.20 \pm 1.3
5		39.70 \pm 1.4	15		54.00 \pm 1.8
6		28.90 \pm 1.2	16		27.20 \pm 1.2
7		38.30 \pm 1.5	17		83.20 \pm 2.2

Table 1 (continued)

Compound	R	IC ₅₀ (μM ± SEM ^a)	Compound	R	IC ₅₀ (μM ± SEM ^a)
8		50.80 ± 1.9	18		30.10 ± 1.2
9		42.80 ± 1.5	19		48.80 ± 1.6
10		30.80 ± 1.2	Standard Thiourea ^b		21.20 ± 1.30


^a Standard deviation.^b Standard drug.

Figure 1 The inhibition of urease by compound 6. (A) Lineweaver–Burk plot of reciprocal of rate of reaction (velocities) vs reciprocal of substrate (urea) in the absence (Δ), and in presence of 20 μM (\blacksquare), 25 μM (\square), 30 μM (\bullet), and 35 μM (\circ) of compound 6. (B) Secondary replot of Lineweaver–Burk plot between the slopes of each line on Lineweaver–Burk plot vs different concentration of compound 6.

Helicobacter pylori (HP), by helping the bacteria to endure at low pH of the stomach during colonization. Thus, it plays a vital role in the pathogenesis of the gastric as well as peptic ulcers which may cause cancer (Devesa et al., 1998). Additionally, urease causes kidney stones formation but also engages in the growth of urolithiasis, pyelonephritis, and hepatic encephalopathy (Martelli et al., 1981). In agriculture, during urea fertilization, high urease activity results in significant environmental and economic losses by discharge of abnormally huge amounts of ammonia in atmosphere. This also leads to plant damage by depriving them from essential nutrients, secondary ammonia toxicity and increase in pH of the soil (Mobley and Hausinger, 1989). Urease inhibition,

therefore, has been identified as first line of treatment of diseases caused by ureolytic bacteria (Saify et al., 2014). Recently reported urease inhibitors are hydroxamate complex (Cheng et al., 2014), homoserine lactone derivative (Czerwonka et al., 2014), thiophosphoric triamides (Ludden et al., 2000), oxadiazoles derivatives (Akhtar et al., 2014), thioureas (Khan et al., 2014b), ethyl 4-(3-benzothioureido) benzoates derivatives (Saeed et al., 2014), Oxindole derivatives (Taha et al., 2015c) and thiobarbituric acid derivatives (Khan et al., 2014c). However, currently available inhibitors are not efficient and the full potential of urease inhibition is yet to be discovered (Font et al., 2008).




Figure 2 The inhibition of urease by compound **10**. (A) Lineweaver–Burk plot of reciprocal of rate of reaction (velocities) vs reciprocal of substrate (urea) in the absence (Δ), and in presence of 20 μM (\blacksquare), 30 μM (\square), 40 μM (\bullet), and 50 μM (\circ) of compound **10**. (B) Secondary replot of Lineweaver–Burk plot between the slopes of each line on Lineweaver–Burk plot vs different concentration of compound **10**.

Table 2 The mode of inhibition of compounds **6**, **10**, **14**, **16**, and **18**.

Compounds	K_i (μM)	Type of inhibition
6	19.10 ± 0.007	Competitive inhibition
10	19.90 ± 0.003	Mixed-type inhibition
14	21.71 ± 0.007	Mixed-type inhibition
16	10.53 ± 0.02	Competitive inhibition
18	18.41 ± 0.003	Mixed-type inhibition
Standard (thiourea)	20.01 ± 0.02	Competitive inhibition

2. Experimental

2.1. General experimental

Melting points were determined on a Büchi 434 melting point apparatus and are uncorrected. NMR was performed on

Bruker AV 300, 400, and 500 MHz instruments, respectively. CHN analyses were determined on a Carlo Erba Strumentazione-Mod-1106, Italy instrument. Infrared (IR) spectra were recorded on a JASCO IR-A-302 spectrometer. Electron impact mass spectra (EI MS) were recorded on a Finnigan MAT-311A, Germany spectrometer. Thin layer chromatography (TLC) was performed on precoated silica gel glass plates (Kieselgel 60, 254, E. Merck, Germany).

2.2. Experimental protocol

2.2.1. General procedure for the synthesis of 3,4,5-trihydroxybenzohydrazide

The methyl 3,4,5-trihydroxybenzoate was refluxed with the mixture of hydrazine hydrated (5 mL) and methanol (15 mL) for 6 h. The excess hydrazine and methanol were evaporated to obtain crude product which was recrystallized by methanol and yielded 92% pure 3,4,5-trihydroxybenzohydrazide.




Figure 3 The inhibition of urease by compound **14**. (A) Lineweaver–Burk plot of reciprocal of rate of reaction (velocities) vs reciprocal of substrate (urea) in the absence (\blacksquare), and in presence of 20 μM (\square), 30 μM (\bullet), and 40 μM (\circ) of compound **14**. (B) Secondary replot of Lineweaver–Burk plot between the slopes of each line on Lineweaver–Burk plot vs different concentration of compound **14**.




Figure 4 The inhibition of urease by compound **16**. (A) Lineweaver–Burk plot of reciprocal of rate of reaction (velocities) vs reciprocal of substrate (urea) in the absence (\blacktriangle), and in presence of 10 μM (\triangle), 15 μM (\blacksquare), 20 μM (\square), 25 μM (\bullet), and 30 μM (\circ) of compound **16**. (B) Secondary replot of Lineweaver–Burk plot between the slopes of each line on Lineweaver–Burk plot vs different concentration of compound **16**.




Figure 5 The inhibition of urease by compound **18**. (A) Lineweaver–Burk plot of reciprocal of rate of reaction (velocities) vs reciprocal of substrate (urea) in the absence (\blacksquare), and in presence of 20 μM (\square), 30 μM (\bullet), and 40 μM (\circ) of compound **18**. (B) Secondary replot of Lineweaver–Burk plot between the slopes of each line on Lineweaver–Burk plot vs different concentration of compound **18**.

2.2.2. General procedure for the synthesis of 3,4,5-trihydroxybenzohydrazone derivatives

The 3,4,5-trihydroxybenzohydrazone derivatives were synthesized by refluxing in methanol a mixture of 2 mmol each of 3,4,5-trihydroxybenzohydrazide with different aldehydes and catalytic amount of acetic acid for 3 h. After the completion of the reaction, the solvent was evaporated by vacuum to afford crude products which were further recrystallized in methanol and got needle like pure product in most of the cases in good to excellent yields.

2.2.2.1. (*E*)-*N'*-(3-chlorobenzylidene)-3,4,5-trihydroxybenzohydrazide (**1**). Yield: 82%. m.p. 172–173 °C; ^1H NMR (500 MHz, $\text{DMSO-}d_6$): δ 11.64 (s, 1H, NH), 9.64 (br. s, 3H, OH), 8.34 (s, 1H, N=CH–Ar), 7.77 (s, 1H), 7.66 (d, 1H, $J = 5.5$ Hz), 7.06 (dd, 1H, $J = 5.5, 2.0$ Hz), (d, 1H, $J = 2.0$ Hz), 6.91(s, 2H); Anal. Calcd for

$\text{C}_{14}\text{H}_{11}\text{ClN}_2\text{O}_4$, C = 54.83, H = 3.62, N = 9.13, Found C = 54.84, H = 3.63, N = 9.15; EI MS m/z (% rel. abund.): 308 ($\text{M} + 2, 6$), 306 ($\text{M}^+, 20$).

2.2.2.2. (*E*)-3,4,5-trihydroxy-*N'*-(4-methoxybenzylidene)benzohydrazide (**2**). Yield: 78%. m.p. 174–175 °C; ^1H NMR (500 MHz, $\text{DMSO-}d_6$): δ 11.70 (s, 1H, NH), 11.40 (s, 1H, OH) 9.88 (br. s, 3H, OH), 8.31 (s, 1H, N=CH–Ar), 7.92 (d, 2H, $J = 8.5$ Hz), 7.06 (d, 2H, $J = 8.5$ Hz), 6.90 (s, 2H), 3.81 (s, 3H, OCH_3); Anal. Calcd for $\text{C}_{15}\text{H}_{14}\text{N}_2\text{O}_5$, C = 59.60, H = 4.67, N = 9.27, Found C = 59.61, H = 4.68, N = 9.26; EI MS m/z (% rel. abund.): 302.

2.2.2.3. (*E*)-3,4,5-trihydroxy-*N'*-(pyridin-2-ylmethylene)benzohydrazide (**3**). Yield: 84%. m.p. 175–176 °C; ^1H NMR (500 MHz, $\text{DMSO-}d_6$): δ 11.48 (s, 1H, NH), 10.54 (s, 1H,

Table 3 Variation in the IR and H NMR of all functional groups present in compound (1–19).

Compound	R	IR (cm ⁻¹)	¹ H NMR
1	3-Cl	715	Due to chlorine electronegativity adjacent proton shifted to downfield
2	4-OCH ₃	1210	The presence of OCH ₃ at δ 3.81
3	2-C=N—C	1640	Due to nitrogen electronegativity adjacent proton shifted to downfield
4	Thiophene C—S—C	540	Due to small ring its proton coupling constants are 4–5 Hz only
5	4-F	1340	Its adjacent proton gave multiple splitting due to fluorine
6	Furan C—O—C	1230	Due to small ring its proton coupling constants are 4–5 Hz only
7	3-C—CH ₃	2950 1440	The presence of CH ₃ at δ 2.36
8	3-OH 4-OCH ₃	3320 1190	The presence of OH δ 9.20 and at 3.86 for OCH ₃
9	4-C=N—C	1635	Due to nitrogen electronegativity adjacent proton shift to downfield
10	2-NO ₂	1460	Due to nitrogen electronegativity adjacent proton shift to downfield
11	3-NO ₂	1430	Due to nitrogen electronegativity adjacent proton shift to downfield
12	4-Cl	740	Due to chlorine electronegativity adjacent proton shift to downfield
13	4-CH ₃	2930 1460	The presence of CH ₃ at δ 2.33
14	3-F	1342	Its adjacent proton gave multiple splitting due to fluorine
15	2-CH ₃	2937 1452	The presence of CH ₃ at δ 2.35
16	3-OH	3340	The presence of OH δ 10.21
17	4-OCH ₃	1190	The presence of OCH ₃ at δ 3.80
18	2-F	1310	Its adjacent proton gave multiple splitting due to fluorine
19	4-COOMe	1710 1220	The presence of OCH ₃ at δ 3.84

OH), 9.70 (br. s, 2H, OH), 9.06 (d, 1H, $J = 2.0$ Hz), 8.70 (dd, 1H, $J = 7.0, 2.0$ Hz), 8.41 (dd, 2H, $J = 2.0, 6.5$ Hz), 8.31 (s, 1H, N=CH—Ar), 7.82 (dd, 1H, $J = 7.0, 6.5$ Hz), 6.94 (s, 2H); Anal. Calcd for Anal. Calcd for C₁₃H₁₁N₃O₄, C = 57.14, H = 4.06, N = 15.38, Found C = 57.15, H = 4.08, N = 15.37; EI MS m/z (% rel. abund.): 273.

2.2.2.4. (*E*)-3,4,5-trihydroxy-*N'*-(thiophen-2-ylmethylene)benzohydrazide (4). Yield: 85%. m.p. 179–180 °C; ¹H NMR (500 MHz, DMSO-*d*₆): δ 11.48 (s, 1H, NH), 9.60 (br. s, 3H, OH), 8.61 (s, 1H, N=CH—Ar), 7.49 (d, 1H, $J = 5.0$ Hz), 7.41 (d, 1H, $J = 3.0$ Hz), 7.22 (dd, 1H, $J = 3.0, 5.0$ Hz), 6.89 (s, 2H); Anal. Calcd for Anal. Calcd for C₁₂H₁₀N₂O₄S, C = 51.79, H = 3.62, N = 10.07, Found C = 59.78, H = 3.63, N = 10.09; EI MS m/z (% rel. abund.): 278.

2.2.2.5. (*E*)-*N'*-(4-fluorobenzylidene)-3,4,5-trihydroxybenzohydrazide (5). Yield: 86%. m.p. 171–172 °C; ¹H NMR (500 MHz, DMSO-*d*₆): δ 11.60 (s, 1H, NH), 9.80 (br. s, 3H, OH), 8.37 (s, 1H, N=CH—Ar), 7.78 (t, 2 H, $J = 5.5$ Hz), 7.33 (t, 1H, $J = 6.0$ Hz), 6.91 (s, 2H); Anal. Calcd for Anal. Calcd for C₁₄H₁₁FN₂O₄, C = 57.93, H = 3.82, N = 9.65, Found C = 57.94, H = 3.83, N = 9.67; EI MS m/z (% rel. abund.): 290.

2.2.2.6. (*E*)-*N'*-(furan-2-ylmethylene)-3,4,5-trihydroxybenzohydrazide (6). Yield: 81%. m.p. 178–179 °C; ¹H NMR (500 MHz, DMSO-*d*₆): δ 11.42 (s, 1H, NH), 9.70 (br. s, 3H, OH), 8.42 (s, 1H, N=CH—Ar), 7.60 (d, 1H, $J = 6.0$ Hz), 7.35 (d, 1H, $J = 4.0$ Hz), 7.41 (d, 1H, $J = 3.0$ Hz), 7.10 (dd, 1H, $J = 4.0, 6.0$ Hz), 6.92 (s, 2H); Anal. Calcd for Anal. Calcd for C₁₂H₁₀N₂O₅, C = 54.97, H = 3.84, N = 10.68,

Found C = 54.96, H = 3.84, N = 10.69; EI MS m/z (% rel. abund.): 262.

2.2.2.7. (*E*)-3,4,5-trihydroxy-*N'*-(3-methylbenzylidene)benzohydrazide (7). Yield: 83%. m.p. 175–176 °C; ¹H NMR (500 MHz, DMSO-*d*₆): δ 11.51 (s, 1H, NH), 9.42 (br. s, 3H, OH), 8.42 (s, 1H, N=CH—Ar), 7.52 (s, 1H), 7.48 (d, 1H, $J = 7.5$ Hz), 7.35 (t, 1H, $J = 7.5$ Hz), 7.10 (d, 1H, $J = 8.0$ Hz), 6.93 (s, 2H), 2.36 (3H, CH₃); Anal. Calcd for Anal. Calcd for C₁₅H₁₄N₂O₄, C = 62.93, H = 4.93, N = 9.79, Found C = 62.94, H = 3.94, N = 9.81; EI MS m/z (% rel. abund.): 286.

2.2.2.8. (*E*)-3,4,5-trihydroxy-*N'*-(3-hydroxy-4-methoxybenzylidene)benzohydrazide (8). Yield: 88%. m.p. 172–173 °C; ¹H NMR (500 MHz, DMSO-*d*₆): δ 11.34 (s, 1H, NH), 9.51 (br. s, 3H, OH), 9.21 (s, 1H, OH), 8.25 (s, 1H, N=CH—Ar), 7.23 (s, 1H), 7.03 (d, 1H, $J = 8.5$ Hz), 6.97 (t, 1H, $J = 8.5$ Hz), 6.90 (s, 2H), 3.86 (3H, OCH₃); Anal. Calcd for Anal. Calcd for C₁₅H₁₄N₂O₆, C = 56.60, H = 4.43, N = 8.80, Found C = 56.62, H = 4.44, N = 8.82; EI MS m/z (% rel. abund.): 318.

2.2.2.9. (*E*)-3,4,5-trihydroxy-*N'*-(pyridin-4-ylmethylene)benzohydrazide (9). Yield: 90%. m.p. 174–175 °C; ¹H NMR (500 MHz, DMSO-*d*₆): δ 11.48 (s, 1H, NH), 10.54 (s, 1H, OH), 9.70 (br. s, 2H, OH), 8.79 (d, 2H, $J = 6.0$ Hz), 8.35 (s, 1H, N=CH—Ar), 7.66 (d, 2H, $J = 6.0, 6.0$ Hz), 6.93 (s, 2H); Anal. Calcd for Anal. Calcd for C₁₃H₁₁N₃O₄, C = 57.14, H = 4.06, N = 15.38, Found C = 57.16, H = 4.09, N = 15.36; EI MS m/z (% rel. abund.): 273.

2.2.2.10. (*E*)-3,4,5-trihydroxy-*N'*-(2-nitrobenzylidene)benzohydrazide (10). Yield: 87%. m.p. 170–171 °C; ¹H NMR (500 MHz, DMSO-*d*₆): δ 11.92 (s, 1H, NH), 9.84 (br. s, 3H, OH), 8.82 (s, 1H, N=CH-Ar), 8.13 (d, 1H, *J* = 7.5 Hz), 8.08 (dd, 1H, *J* = 2.0, 7.0 Hz), 7.89 (t, 1H, *J* = 7.5 Hz), 7.68 (ddd, 1H, *J* = 7.5, 2.0, 2.0 Hz), 6.92 (s, 2H); Anal. Calcd for Anal. Calcd for C₁₄H₁₁N₃O₆, C = 53.00, H = 3.49, N = 13.24, Found C = 53.02, H = 3.50, N = 13.26; EI MS *m/z* (% rel. abund.): 317.

2.2.2.11. (*E*)-3,4,5-trihydroxy-*N'*-(3-nitrobenzylidene)benzohydrazide (11). Yield: 92%. m.p. 171–172 °C; ¹H NMR (500 MHz, DMSO-*d*₆): δ 11.79 (s, 1H, NH), 9.74 (br. s, 3H, OH), 8.52 (s, 1H), 8.46 (s, 1H, N=CH-Ar), 8.26 (dd, 1H, *J* = 6.5, 2.0 Hz), 8.13 (d, 1H, *J* = 7.5 Hz), 7.77 (t, 1H, *J* = 8.0 Hz), 6.95 (s, 2H); Anal. Calcd for Anal. Calcd for C₁₄H₁₁N₃O₆, C = 53.00, H = 3.49, N = 13.24, Found C = 53.01, H = 3.51, N = 13.25; EI MS *m/z* (% rel. abund.): 317.

2.2.2.12. (*E*)-*N'*-(4-chlorobenzylidene)-3,4,5-trihydroxybenzohydrazide (12). Yield: 90%. m.p. 180–181 °C; ¹H NMR (500 MHz, DMSO-*d*₆): δ 11.60 (s, 1H, NH), 9.65 (br. s, 3H, OH), 8.35 (s, 1H, N=CH-Ar), 7.74 (d, 2H, *J* = 8.0 Hz), 7.50 (d, 2H, *J* = 8.0, Hz), 6.90 (s, 2H); Anal. Calcd for Anal. Calcd for C₁₄H₁₁ClN₂O₄, C = 54.83, H = 3.62, N = 9.13, Found C = 54.84, H = 3.61, N = 9.14; EI MS *m/z* (% rel. abund.): 308 (M + 2, 20), 306 (M⁺, 60).

2.2.2.13. (*E*)-3,4,5-trihydroxy-*N'*-(4-methylbenzylidene)benzohydrazide (13). Yield: 87%. m.p. 177–178 °C; ¹H NMR (500 MHz, DMSO-*d*₆): δ 11.44 (s, 1H, NH), 9.80 (br. s, 3H, OH), 8.33 (s, 1H, N=CH-Ar), 7.60 (d, 2H, *J* = 8.0 Hz), 7.27 (d, 2H, *J* = 8.0, Hz), 6.90 (s, 2H), 2.33 (3H, CH₃); Anal. Calcd for Anal. Calcd for C₁₅H₁₄N₂O₄, C = 62.93, H = 4.93, N = 9.79, Found C = 62.94, H = 4.92, N = 9.80; EI MS *m/z* (% rel. abund.): 286.

2.2.2.14. (*E*)-*N'*-(3-fluorobenzylidene)-3,4,5-trihydroxybenzohydrazide (14). Yield: 80%. m.p. 175–176 °C; ¹H NMR (500 MHz, DMSO-*d*₆): δ 11.63 (s, 1H, NH), 9.70 (br. s, 3H, OH), 8.37 (s, 1H, N=CH-Ar), 7.54–7.46 (m, 3 H), 7.33 (td, 1H, *J* = 6.5, 2.0 Hz), 6.91 (s, 2H); Anal. Calcd for Anal. Calcd for C₁₄H₁₁FN₂O₄, C = 57.93, H = 3.82, N = 9.65, Found C = 57.95, H = 3.81, N = 9.66; EI MS *m/z* (% rel. abund.): 290.

2.2.2.15. (*E*)-3,4,5-trihydroxy-*N'*-(2-methylbenzylidene)benzohydrazide (15). Yield: 82%. m.p. 169–170 °C; ¹H NMR (500 MHz, DMSO-*d*₆): δ 11.40 (s, 1H, NH), 9.60 (br. s, 3H, OH), 8.69 (s, 1H, N=CH-Ar), 7.85 (d, 1H, *J* = 7.5 Hz), 7.31–7.23 (m, 3H), 6.92 (s, 2H), 2.35 (3H, CH₃); Anal. Calcd for Anal. Calcd for C₁₅H₁₄N₂O₄, C = 62.93, H = 4.93, N = 9.79, Found C = 62.94, H = 4.94, N = 9.81; EI MS *m/z* (% rel. abund.): 286.

2.2.2.16. (*E*)-3,4,5-trihydroxy-*N'*-(3-hydroxybenzylidene)benzohydrazide (16). Yield: 90%. m.p. 172–173 °C; ¹H NMR (500 MHz, DMSO-*d*₆): δ 11.47 (s, 1H, NH), 10.21 (s, 1H, OH), 9.74 (br. s, 3H, OH), 8.32 (s, 1H, N=CH-Ar), 7.26 (t, 1H, *J* = 8.0 Hz), 7.16 (s, 1H), 7.07 (d, 1H, *J* = 8.0 Hz), 6.92 (s, 2H), 7.16 (dd, 1H, *J* = 8.0, 2.0 Hz); Anal. Calcd for

Anal. Calcd for C₁₄H₁₂N₂O₅, C = 58.33, H = 4.20, N = 9.72, Found C = 58.34, H = 4.21, N = 9.71; EI MS *m/z* (% rel. abund.): 288.

2.2.2.17. (*E*)-3,4,5-trihydroxy-*N'*-(3-methoxybenzylidene)benzohydrazide (17). Yield: 82%. m.p. 170–171 °C; ¹H NMR (500 MHz, DMSO-*d*₆): δ 11.53 (s, 1H, NH), 9.74 (br. s, 3H, OH), 8.33 (s, 1H, N=CH-Ar), 7.26 (t, 1H, *J* = 7.5 Hz), 7.30 (s, 1H), 7.26 (d, 1H, *J* = 8.0 Hz), 6.99 (dd, 1H, *J* = 8.0, 2.0 Hz) 6.91 (s, 2H), (s, 3H, OCH₃); Anal. Calcd for Anal. Calcd for C₁₅H₁₄N₂O₅, C = 59.60, H = 4.67, N = 9.27, Found C = 59.61, H = 4.66, N = 9.28; EI MS *m/z* (% rel. abund.): 302.

2.2.2.18. (*E*)-*N'*-(2-fluorobenzylidene)-3,4,5-trihydroxybenzohydrazide (18). Yield: 90%. m.p. 171–172 °C; ¹H-NMR (500 MHz, DMSO-*d*₆): δ 11.68 (s, 1H, NH), 9.50 (br. s, 3H, OH), 8.66 (s, 1H, N=CH-Ar), 7.92 (t, 3 H, *J* = 6.5 Hz), 7.48–7.46 (m, 1H), 7.31–7.26 (m, 2H), 6.94 (s, 2H); Anal. Calcd for Anal. Calcd for C₁₄H₁₁FN₂O₄, C = 57.93, H = 3.82, N = 9.65, Found C = 57.94, H = 3.83, N = 9.64; EI MS *m/z* (% rel. abund.): 290.

2.2.2.19. (*E*)-Methyl 4-((2-(3,4,5-trihydroxybenzo)hydrazono)methyl)benzoate (19). Yield: 92%. m.p. 180–181 °C; ¹H NMR (500 MHz, DMSO-*d*₆): δ 11.60 (s, 1H, NH), 9.40 (br. s, 3H, OH), 8.36 (s, 1H, N=CH-Ar), 8.20 (d, 2H, *J* = 8.0 Hz), 7.84 (d, 2H, *J* = 8.0, Hz), 6.91 (s, 2H), 3.80 (3H, OCH₃); Anal. Calcd for Anal. Calcd for C₁₆H₁₄N₂O₆, C = 58.18, H = 4.27, N = 8.48, Found C = 58.19, H = 4.28, N = 8.49; EI MS *m/z* (% rel. abund.): 314.

2.2.3. Urease assay and inhibition

The reaction mixtures, comprising 25 μL of enzyme (jack bean urease) solution and 55 μL of buffers containing 100 mM urea, were incubated with 5 μL of the test compounds (0.5 mM concentration) at 30 °C for 15 min in 96-well plates. For the kinetics assessment the urea concentrations were changed from 2 to 24 mM. Urease activity was determined by measuring ammonia production using the indophenol method as described by Weatherburn (1967). Briefly, 45 μL of phenol reagent (1% w/v phenol and 0.005% w/v sodium nitropruside) and, 70 μL of alkali reagent (0.5% w/v NaOH and 0.1% active chloride NaOCl) were added to each well. The increasing absorbance at 630 nm was measured after 50 min, using a microplate reader (Molecular Device, USA). All reactions were performed in triplicate in a final volume of 200 μL. The results (change in absorbance per min) were processed by using SoftMaxPro software (molecular Device, USA). The entire assays were performed at pH 6.8. Percentage inhibition was calculated from the formula $100 \cdot (\text{OD}_{\text{test well}} / \text{OD}_{\text{control}}) \times 100$. Thiourea was used as the standard inhibitor for urease (Khan et al., 2014d).


3. Results and discussion

3.1. Chemistry

In the continuation of our research on enzyme inhibition (Rahim et al., 2015a,b; Taha et al., 2015d; Abdullah et al., 2015; Khan et al., 2014e) 3,4,5-trihydroxybenzohydrazones

(1–19) were synthesized from 3,4,5-trihydroxybenzohydrazide which were obtained from methyl 3,4,5-trihydroxybenzoate by refluxing with hydrazine hydrate for 4 h. The 3,4,5-trihydroxybenzohydrazide obtained was recrystallized from methanol. 3,4,5-Trihydroxybenzohydrazones were prepared by refluxing 3,4,5-trihydroxybenzohydrazide with differently substituted aldehydes 1–19 in methanol for 3–4 h (Scheme 1). The crude products obtained were recrystallized in methanol and mostly needle like crystals were obtained in 74–87% yield. The structures of 3,4,5-trihydroxybenzohydrazones were deduced by using various spectroscopic techniques and CHN analyses.

Table 1 Derivatives of 3,4,5-Trihydroxybenzohydrazone 1–19.



3.2. Urease inhibition

In the continuation of our work, on enzyme inhibition we synthesized 1–19 3,4,5-trihydroxybenzohydrazones. They were evaluated for urease inhibition. The compounds 16, 6, 18, 14 and 10 showed good activities. The compounds 1, 4, 7, 5, 11 and 9, 3, 19 showed moderate activities while, compounds 8, 12, 15, 13 and 17 showed weak activity (Table 1).

The compound 16 ($IC_{50} = 27.20 \pm 1.2 \mu\text{M}$) was found to be the most active among the series of nineteen compounds. It was found that this activity is due to the hydroxyl group present at the 3' position and this was confirmed by compound 17 ($IC_{50} = 83.20 \pm 2.2 \mu\text{M}$) in which hydroxyl group is replaced by methoxy substituent which resulted in the decrease of activity by almost 3-fold. Compound 8 ($IC_{50} = 50.80 \pm 1.9 \mu\text{M}$) having 3'-hydroxy-4'-methoxy showed less activity than compound 16. This might be due to the bulky methoxy group at 4'-position, which causes compound 8 to become structurally non-compatible toward urease enzyme. The compound 2 ($IC_{50} = 57.40 \pm 2.2 \mu\text{M}$) having 4'-methoxy showed only weak activity further proved the significance of hydroxy at position 3'.

The compound 6 ($IC_{50} = 28.90 \pm 1.2 \mu\text{M}$) was found to be the second most active compound of the series and its activity is due to the furan ring which would be having interaction with enzyme.

Compound 4 ($IC_{50} = 38.40 \pm 1.4 \mu\text{M}$), which is a thiophene derivative, showed less activity as compared to the compound 6 (consists of furan ring) and this may be due to large size and low electronegative nature of sulfur as compared to oxygen. Higher electronegativity effect of oxygen allows furan-containing derivative 6 to bind better through hydrogen bonding with urease enzyme as compared to thiophene moiety of compound 4.

Among the pyridine derivatives, compound 9 ($IC_{50} = 42.80 \pm 1.5 \mu\text{M}$), which is 4'-pyridinyl derivative, showed good activity as compared to its positional isomer 2'-pyridene analogue 3 ($IC_{50} = 47.40 \pm 1.8 \mu\text{M}$).

The compound 18 ($IC_{50} = 30.10 \pm 1.2 \mu\text{M}$) having fluorine atom at 2'-postion and compound 14

($IC_{50} = 30.20 \pm 1.3 \mu\text{M}$) having fluorine atom at 3'-postion showed similar activity while interestingly its other positional isomer compound 5 ($IC_{50} = 39.70 \pm 1.4 \mu\text{M}$), having fluorine atom at 4'-postion, exhibited slightly lower reactivity. Therefore, the order of reactivity of fluorinated derivative was found to be 2'-F > 3'-F > 4'-F.

Other halogen substituted, compounds 1 ($IC_{50} = 37.30 \pm 1.4 \mu\text{M}$) and 12 ($IC_{50} = 53.90 \pm 1.8 \mu\text{M}$) exhibited the same activity trend, such as, 3'-Cl > 4'-Cl. The compound 10 ($IC_{50} = 30.80 \pm 1.2 \mu\text{M}$) having 2'-nitro substituent showed good activity but its other isomer having 3'-nitro showed weak activity.

The compound 7 having 3'-methyl showed good activity as compared to its other analogues having 2'-methyl, compound 15 ($IC_{50} = 54.00 \pm 1.8 \mu\text{M}$) and 4'-methyl, compound 13 ($IC_{50} = 55.40 \pm 1.9 \mu\text{M}$). Their order of reactivity was found to be 3'-methyl > 2'-methyl > 4'-methyl, while the compound 19 ($IC_{50} = 48.80 \pm 1.6 \mu\text{M}$) having ester group showed moderate activity.

To investigate the inhibition mechanism of this series, the kinetic studies on five most active compounds 6, 10, 14, 16 and 18 were performed, with different concentrations of test compounds and substrates. Enzyme reaction is the first order reaction and the enzyme kinetics were used for only the determination of type of inhibition and K_i value. From kinetic studies, it was inferred that compounds 6 and 16 are competitive inhibitors with K_i values 19.1 ± 0.007 and $10.53 \pm 0.02 \mu\text{M}$, respectively (Figs. 1 and 2). The type of inhibition was determined by Lineweaver–Burk plots. The reciprocal of the rate of the reaction was plotted against the reciprocal of substrate concentration to monitor the effect of inhibitor on both K_m and V_{max} . Figs. 1 and 2 showed that in the presence of compounds 6 and 16, the V_{max} of jack bean urease enzyme was not affected, while the K_m of enzyme increased, which indicates the competitive inhibition (Table 2).


The secondary replots of Lineweaver–Burk plots (Lodhi et al., 2007; Muhammad Et al., 2014) were plotted to determine the K_i value (Fig. 2). The K_i values were calculated by plotting the slope of each line in the Lineweaver–Burk plots against different concentrations of compounds 6 and 16. The K_i value was confirmed from Dixon plot, by plotting the reciprocal of the rate of reaction against the different concentrations of compounds 6 and 16.

The kinetic studies of compounds 10, 14 and 18 indicated that these are mixed-type of inhibitors with K_i values between 18.41 and 21.71 μM (Figs. 3–5). The Lineweaver–Burk plots of compounds 10, 14 and 18 showed that in the presence of compounds 10, 14 and 18, both the V_{max} and K_m of jack bean urease were affected. In the presence of compounds 10, 14 and 18 the V_{max} of jack bean urease was decreased, while the K_m was increased, which indicated the mixed-type of inhibition. Again for K_i determination of compounds 10, 14 and 18 the secondary replots of Lineweaver–Burk plots and Dixon plot were used.

4. Difference in IR and NMR data responsible for inhibition activity

The first ring of compounds (1–19) is common. The variation in inhibition potential is mainly due to the functional group present on second ring. We can easily distinguish by IR and

NMR by observing the pick of functional group. In case of NMR inactive functional group we can see the variation in Chemical shift of adjacent Proton Table 3.



5. Conclusion

In this study, we synthesized 3,4,5-trihydroxybenzohydrazones (1–19) and evaluated them for their urease inhibition activity. The results for urease inhibition showed excellent activity, close to the standard thiourea. We found new class of urease inhibitors. The kinetic studies on the five most active compounds 6, 10, 14, 16 and 18 were carried out. The compounds 6 and 16 were found to be competitive inhibitors and the compounds 10, 14 and 18 were found to be mixed-type of inhibitors.

Acknowledgments

Authors want to thank Universiti Teknologi Mara (UITM) Puncak Alam Campus for providing excellent laboratory facilities for the research and all technical and nontechnical staff of Atta-ur-Rahman Institute for Natural Product Discovery (RiND) for a lot of support for this work.

References

Abdullah, N.K.N.Z., Taha, M., Ahmat, N., Wadood, A., Ismail, N.H., Rahim, F., Ali, M., Abdullah, N., Khan, K.M., 2015. Novel 2,5-disubstituted-1,3,4-oxadiazoles with benzimidazole backbone: a new class of β -glucuronidase inhibitors and in silico studies. *Bioorg. Med. Chem.* 23, 3119–3125.

Akhtar, T., Khan, M.A., Iqbal, J., Jones, P.G., Hameed, S., 2014. A facile one pot synthesis of 2-arylamino-5-aryloxyalkyl-1,3,4-oxadiazoles and their urease inhibition studies. *Chem. Biol. Drug* 84, 92–98.

Aziz, A.N., Taha, M., Ismail, N.H., Anouar, E.H., Yousof, S., Jamil, W., Awang, K., Ahmat, N., Khan, K.M., Kashif, S.M., 2014. Synthesis, crystal structure, DFT studies and evaluation of the antioxidant activity of 3,4-dimethoxybenzenamine Schiff bases. *Molecules* 19, 8414–8433.

Caffery, C.R., Schanz, M., Nkemgu-Njinkeng, J., Brush, M., Hansell, E., Cohen, F.E., Flaherty, T.M., Mckerrow, J.H., Steverding, D., 2002. Screening of acyl hydrazide proteinase inhibitors for antiparasitic activity against *Trypanosoma brucei*. *Int. J. Antimicrob. Agents* 19, 227–231.

Cheng, X.-S., Zhang, J.-C., You, Z.-L., Wang, X., Li, H.-H., 2014. Synthesis, structures, and *Helicobacter pylori* urease inhibition of hydroxamate-coordinated oxovanadium complexes with benzohydrazone ligands. *Trans. Metal Chem.* 3, 291–297.

Cimerman, Z., Miljanić, S., Galic, N., 2000. Schiff bases derived from aminopyridines as spectrofluorimetric analytical reagents. *Croat. Chem. Acta* 73, 81–95.

Cunha, A.C., Figueiredo, J.M., Tributino, J.L.M., Miranda, A.L.P., Castro, H.C., Zingali, R.B., Fraga, C.A.M., de Souza, M.C.B.V.,

Ferreira, Barreiro, E.J., 2003. Antiplatelet properties of novel N-substituted-phenyl-1,2,3-triazole-4-acylhydrazone derivatives. *Bioorg. Med. Chem.* 11, 2051–2059.

Czerwonka, G., Arabski, M., Wasik, S., Jablonska-Wawrzycka, A., Rogala, P., Kaca, W., 2014. Morphological changes in *Proteus mirabilis* O18 biofilm under the influence of a urease inhibitor and a homoserine lactone derivative. *Arch. Micro.* 196, 169–177.

Devesa, S.S., Blot, W.J., Fraumeni, J.F., 1998. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. *J. Cancer* 83, 2049–2053.

Font, M., Domínguez, M.J., Sanmartín, C., Palop, J.A., San-Francisco, S., Urrutia, O., Houdusse, F., García-Mina, J.M., 2008. Structural characteristics of phosphoramidate derivatives as urease inhibitors. Requirements for activity. *J. Agric. Food Chem.* 56, 8451–8460.

Greenfield, R.S., Kaneko, T., Daues, A., Edson, M.A., Fitzgerald, K.A., Olech, L.J., Grattan, J.A., Spitalny, G.L., Braslawsky, G.R., 1990. Evaluation in vitro of adriamycin immunoconjugates synthesized using an acid-sensitive hydrazone linker. *Cancer Res.* 50, 6600–6607.

Imran, S., Taha, M., Ismail, N.H., Khan, K.M., Naz, F., Hussain, M., Tauseef, S., 2014. Synthesis of novel bisindolylmethane Schiff bases and their antibacterial activity. *Molecules* 19, 11722–11740.

Jamil, W., Perveen, S., Shah, S.A.A., Taha, M., Ismail, N.H., Perveen, S., Ambreen, N., Khan, K.M., Choudhary, M.I., 2014. Phenoxyacetohydrazide Schiff bases: β -glucuronidase inhibitors. *Molecules* 19, 8788–8802.

Jamil, W., Solangi, S., Ali, M., Khan, K.M., Taha, M., Khuhawar, M.Y., 2015. Syntheses, characterization, in vitro antiglycation and DPPH radical scavenging activities of isatin salicylhydrazidehydrazone and its Mn (II), Co (II), Ni (II), Cu (II), and Zn (II) metal complexes. *Arabian J. Chem* (in press) (<http://dx.doi.org/10.1016/j.arabjc.2015.02.015>).

Kabak, M., Elmali, A., Elerman, Y., 1999. Keto-enol tautomerism, conformations and structure of N-(2-hydroxy-5-methylphenyl), 2-hydroxybenzaldehyde-imine. *J. Mol. Struct.* 477, 151–158.

Kaymakçioğlu, K.B., Oruç, E.E., Unsalan, S., Kandemirli, F., Shvets, N., Rollas, S., Anatholy, D., 2006. Synthesis and characterization of novel hydrazide-hydrazones and the study of their structure antituberculosis activity. *Eur. J. Med. Chem.* 41, 1253–1261.

Khan, K.M., Siddiqui, S., Saleem, M., Taha, M., Saad, S.M., Perveen, S., Choudhary, M.I., 2014a. Synthesis of triazole derivatives of schiff bases: novel inhibitors of nucleotide pyrophosphatase/phosphodiesterase-1. *Bioorg. Med. Chem.* 22, 6509–6514.

Khan, K.M., Naz, F., Taha, M., Khan, A., Perveen, S., Choudhary, M.I., Voelter, W., 2014b. Synthesis and in vitro urease inhibitory activity of N, N'-Disubstituted thioureas. *Eur. J. Med. Chem.* 74, 314–323.

Khan, K.M., Rahim, F., Khan, A., Shabeer, M., Hussain, S., Rehman, W., Taha, M., Khan, M., Perveen, S., Choudhary, M.I., 2014c. Synthesis and structure-activity relationship of thiobarbituric acid derivatives as potent inhibitors of urease. *Bioorg. Med. Chem.* 22, 4119–4123.

Khan, K.M., Rahim, F., Wadood, A., Kosar, N., Taha, M., Khan, A., Fakhri, M.I., Junaid, M., Rehman, W., Khan, M., Perveen, S., Abid, O.B., Mohammad, M., Sajid, Choudhary, M.I., 2014d. Synthesis and molecular docking studies of Potent α -glucosidase inhibitors based on biscoumarin skeleton. *Eur. J. Med. Chem.* 81, 245–252.

Khan, K.M., Ambreen, Nida, Taha, M., Halim, S.A., Zaheer-ul-Haq, Naureen, S., Rasheed, S., Perveen, S., Ali, S., Choudhary, M.I., 2014e. Structure-based design, synthesis and biological evaluation of β -glucuronidase inhibitors. *J. Comput. Aided Mol. Des.* 28, 577–585.

Küçükgül, S.G., Rollas, S., 2002. Synthesis, characterization of novel coupling products and 4-arylhydrazono-2-pyrazoline-5-ones as potential antimycobacterial agents. *Il Farmaco* 57, 583–587.

- Küçükgülzel, S.G., Mazi, A., Sahin, F., Öztürk, S., Stables, J., 2003. Synthesis and biological activities of diflunisal hydrazide-hydrazones. *Eur. J. Med. Chem.* 38, 1005–1013.
- Küçükgülzel, I., Küçükgülzel, S.G., Rollas, S., Otuk-Saniş, G., Özdemir, O., Bayrak, İ., Altuğ, T., Stables, J.P., 2004. Synthesis of some 3-(aryalkylthio)-4-alkyl/aryl-5-(4-aminophenyl)-4H-1,2,4-triazole derivatives and their anticonvulsant activity. *Il Farmaco* 59, 839–891.
- Lima, P.C., Lima, L.M., da Silva, K.C., Léda, P.H., de Miranda, A.L., Fraga, C.A., Barreiro, E.J., 2000. Synthesis and analgesic activity of novel N-acylarylhydrazones and isomers, derived from natural safrole. *Eur. J. Med. Chem.* 35, 187–203.
- Lodhi, M.A., Abbasi, M.A., Choudhary, M.I., Ahmad, V.U., 2007. Kinetics studies on triacontanyl palmitate: a urease inhibitor. *Nat. Prod. Res.* 21, 721–725.
- Loncle, C., Brunel, J.M., Vidal, N., Dherbomez, M., Letourneux, Y., 2004. Synthesis and antifungal activity of cholesterol-hydrazone derivatives. *Eur. J. Med. Chem.* 39, 1067–1071.
- Ludden, P.A., Harmon, D.L., Larson, B.T., Axe, D.E., 2000. Influence of the novel urease inhibitor N-(n-butyl) thiophosphoric triamide on ruminant nitrogen metabolism: I. In vitro urea kinetics and substrate digestion. *J. Anim. Sci.* 78, 181–187.
- Martelli, A., Buli, P., Cortecchia, V., 1981. Urease inhibitor therapy in infected renal stones. *Eur. Urol.* 7, 291–293.
- Melnik, P., Leroux, V., Sergheraert, C., Grellier, P., 2006. Design, synthesis and in vitro antimalarial activity of an acylhydrazone library. *Bioorg. Med. Chem. Lett.* 16, 31–35.
- Mobley, H.L.T., Hausinger, R.P., 1989. Microbial ureases: significance, regulation, and molecular characterization. *J. Microbiol. Rev.* 53, 85–108.
- Muhammad, N., Saeed, M., Khan, A., Adhikari, A., Wadood, A., Khan, K.M., Feo, V.D., 2014. A new urease inhibitor from *Viola betonicifolia*. *Molecules* 19, 16770–16778.
- Pandeya, S.N., Sriram, D., Nath, G., DeClercq, E., 1999. Synthesis, antibacterial, antifungal and anti-HIV activities of Schiff and Mannich bases derived from isatin derivatives and N-[4-(4'-chlorophenyl)thiazol-2-yl] thiosemicarbazide. *Eur. J. Pharm. Sci.* 9, 25–31.
- Ragnarsson, U., 2001. Synthetic methodology for alkyl substituted hydrazines. *Chem. Soc. Rev.* 30, 205–213.
- Rahim, F., Ullah, K., Ullah, H., Wadood, A., Taha, M., Rehman, A.U., uddin, I., Ashraf, M., Shaikat, A., Rehman, W., Hussain, S., Khan, K.M., 2015a. Triazinoindole analogs as potent inhibitors of α -glucosidase: synthesis, biological evaluation and molecular docking studies. *Bioorg. Chem.* 58, 81–87.
- Rahim, F., Malik, F., Ullah, H., Wadood, A., Khan, F., Javid, M.T., Taha, M., Rehman, W., Rehman, A.U., Khan, K.M., 2015b. Isatin based Schiff bases as inhibitors of α -glucosidase: synthesis, characterization, in vitro evaluation and molecular docking studies. *Bioorg. Chem.* 60, 42–48.
- Saeed, A., Khan, M.S., Rafique, H., Shahid, M., Iqbal, J., 2014. Design, synthesis, molecular docking studies and in vitro screening of ethyl 4-(3-benzothioureido) benzoates as urease inhibitors. *Bioorg. Chem.* 52, 1–7.
- Saify, Z.S., Kamil, A., Akhtar, S., Taha, M., Khan, A., Khan, K.M., Jahan, S., Rahim, F., Perveen, S., Choudhary, M.I., 2014. 2-(2'-pyridyl) benzimidazole derivatives and their urease inhibitory activity. *Med. Chem. Res.* 23, 4447–4454.
- Sawada, Y., Yanai, T., Nakagawa, H., Tsukamoto, Y., Tamagawa, Y., Yokoi, S., Yanagi, M., Toya, T., Sugizaki, H., Kato, Y., Shirakura, H., Watanabe, T., Yajima, Y., Kodama, S., Masui, A., 2003. Synthesis and insecticidal activity of benzoheterocyclic analogues of N'-benzo-N-(tert-butyl)benzohydrazide: Part 1. Design of benzoheterocyclic analogues. *Pest Manag. Sci.* 59, 25–35.
- Taha, M., Baharudin, M.S., Ismail, N.H., Khan, K.M., Jaafar, F.M., Samreen, S., Siddiqui, S., Choudhary, M.I., 2013. Synthesis of 2-methoxybenzohydrazone and evaluation of their antileishmanial activity. *Bioorg. Med. Chem. Lett.* 23, 3463–3466.
- Taha, M., Ismail, N.H., Jamil, W., Rashwan, H., Kashif, S.M., Sain, A.A., Adenan, M.I., Anouar, E.H., Ali, M., Rahim, F., Khan, K.M., 2014. Synthesis of novel derivatives of 4-methylbenzimidazole and evaluation of their biological activities. *Eur. J. Med. Chem.* 84, 731–738.
- Taha, M., Ismail, N.H., Lalani, S., Fatmi, M.Q., Atia-tul-Wahab, Siddiqui, S., Khan, K.M., Imran, Syahrul., Choudhary, M.I., 2015a. Synthesis of novel inhibitors of α -glucosidase based on the benzothiazole skeleton containing benzohydrazide moiety and their molecular docking studies. *Eur. J. Med. Chem.* 92, 387–400.
- Taha, M., Ismail, N.H., Khan, A., Syed, A.A.S., Anwar, A., Halim, S.A., Fatmi, M.Q., Imran, S., Rahim, F., Khan, K.M., 2015b. Synthesis of novel derivatives of oxindole, their urease inhibition and molecular docking studies. *Bioorg. Med. Chem. Lett.* 25, 3285–3289. <http://dx.doi.org/10.1016/j.bmcl.2015.05.069>.
- Taha, M., Ismail, N.H., Baharudin, M.S., Lalani, S., Mehboob, S., Khan, K.M., yousuf, S., Siddiqui, S., Rahim, F., Choudhary, M. I., 2015c. Synthesis crystal structure of 2-methoxybenzoylhydrazones and evaluation of their α -glucosidase and urease inhibition potential. *Med. Chem. Res.* 24, 1310–1324.
- Taha, M., Ismail, N.H., Imran, S., Selvaraj, M., Rashwan, H., Farhanah, F.U., Rahim, F., Selvarajan, K.K., Ali, M., 2015d. Synthesis of benzimidazole derivatives as potent β -glucuronidase inhibitors. *Bioorg. Chem.* 61, 36–44.
- Tarafder, M.T., Kasbollah, A., Saravan, N., Crouse, K.A., Ali, A.M., Tin, O.K., 2002. S-methyldithiocarbamate and its Schiff bases: evaluation of bondings and biological properties. *J. Biochem. Mol. Biol. Biophys.* 6, 85–91.
- Todeschini, A.R., de Miranda, A.L., Silva, C.M., Parrini, S.C., Barreiro, E.J., 1998. Synthesis and evaluation of analgesic, anti-inflammatory and antiplatelet properties of new 2-pyridylarylhydrazones derivatives. *Eur. J. Med. Chem.* 33, 189–199.
- Weatherburn, M.W., 1967. Phenol-hypochlorite reaction for determination of ammonia. *Anal. Chem.* 39, 971–974.